ESR1 and breast neoplasm: Among these targets, the hypermethylation of RASSF1A, BRCA1, RARB, and RARB2, in estrogen receptor+ (ER+) and progesterone receptor (PR+) breast tumors and plasmas, were validated as indicators of poor prognosis in at least two independent studies [140].